EGFR and cancer: In 2015 European Cancer Congress (ECC), R.A. Stahel et al. reported that patients with EGFR T790M mutation received bevacizumab plus erlotinib had a significant longer PFS than those without EGFR T790M mutation (median PFS 16.0 vs. 10.5 months).